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Abstract
Background: HOTTIP, a long non-coding RNA located in the HOXA cluster, plays a role in the patterning of tissues
with mesodermal components, including the lung. Overexpression of HOXA genes, including HOTTIP, has been
associated with a more aggressive phenotype in several cancers. However, the prognostic impact of HOTTIP has not
yet been explored in non-small-cell lung cancer (NSCLC). We have correlated HOTTIP expression with time to
relapse (TTR) and overall survival (OS) in early-stage NSCLC patients.
Methods: Ninety-nine early-stage NSCLC patients who underwent surgical resection in our center from June 2007
to November 2013 were included in the study. Mean age was 66; 77.8% were males; 73.7% had stage I disease; and
55.5% had adenocarcinoma. A validation data set comprised stage I-II patients from The Cancer Genome Atlas
(TCGA) Research Network.
Results: HOTTIP was expressed in all tumor samples and was overexpressed in squamous cell carcinoma (p = 0.007)
and in smokers (p = 0.018). Patients with high levels of HOTTIP had shorter TTR (78.3 vs 58 months; p = 0.048) and
shorter OS (81.2 vs 61 months; p = 0.023) than those with low levels. In the multivariate analysis, HOTTIP emerged as
an independent prognostic marker for TTR (OR: 2.05, 95%CI: 1–4.2; p = 0.05), and for OS (OR: 2.31, 95%CI: 1.04–5.1;
p = 0.04). HOTTIP was validated as a prognostic marker for OS in the TCGA adenocarcinoma cohort (p = 0.025).
Moreover, we identified a 1203-mRNA and a 61-miRNA signature that correlated with HOTTIP expression.
Conclusions: The lncRNA HOTTIP can be considered a prognostic biomarker in early-stage NSCLC.
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Background
According to the American Cancer Society, in 2018,
lung cancer will be the second most frequent cancer in
the United States of America in both males and females
(14 and 13%, respectively, of all cancers) and the first
leading cause of death by cancer (26 and 25%, respect-
ively) [1]. Non-small-cell lung cancer (NSCLC), the most
frequent subtype, accounts for 85% of all lung cancers.
Despite years of research, the prognosis for patients with
NSCLC remains dismal, with a 5-year relative survival
rate of 18% for all stages combined (www.cancer.net). In
the 30% of patients that debut with early-stage disease
(stage I-II), the cornerstone of treatment is the surgical
removal of the tumor. Moreover, in stage IB disease with
a primary tumor > 4 cm and in stage II disease, adjuvant
chemotherapy (usually cisplatin-vinorelbine) has proven
to be beneficial, with a 4–5% absolute survival improve-
ment at five years [2]. A large study including 1294 con-
secutive early-stage NSCLC patients who underwent
surgery showed that after a median follow up of 35
months, 20% of patients had relapsed and 7% were diag-
nosed with a second primary lung cancer [3]. These data
highlight the need to further investigate this disease and
consolidate useful prognostic markers.
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Up to 70% of our genome is transcribed into
non-coding RNAs (ncRNAs) that do not serve as tem-
plates for proteins. These ncRNAs are subdivided into two
major groups: small ncRNAs (< 200 nt) and long ncRNAs
(lncRNAs) (> 200 nt) [4]. Although small ncRNAs, espe-
cially microRNAs (miRNAs), have been the most exten-
sively studied [5], lncRNAs have recently emerged as
worthy biomarkers, since their expression is highly cell
type- and tissue-specific [6]. In NSCLC, several lncRNAs
are involved in the carcinogenesis process, some of which
have been associated with patient survival [7–9].
The HOX family genes are known transcription fac-
tors with a key role in embryogenesis and carcinogen-
esis [10, 11]. Their expression is dysregulated in
several cancers, including NSCLC [11–14]. In humans,
HOX genes are organized into four clusters (A, B, C, and
D), which are located on different chromosomes [15].
Interestingly, several lncRNAs associated with HOX gen-
omic regions can participate in the regulation of HOX
genes and collaborate in their functions [16]. HOTTIP,
also known as HOXA distal transcript antisense RNA, is
an antisense lncRNA located in the HOXA cluster that co-
ordinates the activation of several 5′ HOXA genes in vivo
[17]. It is overexpressed in several cancers [18–20], includ-
ing NSCLC, where its overexpression in vitro has been as-
sociated with increased proliferation and invasion of lung
cancer cells through transcriptional regulation of HOXA13
[21]. Moreover, HOTTIP overexpression has been associ-
ated with worse outcome in several tumors, including he-
patocellular carcinoma [22], tongue squamous cell
carcinoma [18], colorectal cancer [20], osteosarcoma [23],
breast cancer [24], gastric cancer [19], and even small-cell
lung cancer [25]. To date, however, the prognostic impact
of HOTTIP expression levels in NSCLC has not been ex-
plored [26, 27].
In the present study, we have analyzed HOTTIP ex-
pression in a cohort of 99 patients with early-stage
NSCLC who underwent surgical resection in our center
and have correlated HOTTIP expression levels with
overall survival (OS) and time to relapse (TTR).
Methods
Patients
A total of 99 early-stage NSCLC patients who under-
went complete surgical resection in Hospital Clínic (Bar-
celona) from May 2007 to October 2013 were included
in the study. Prospectively collected tumor tissues were
stored in RNALater® (Ambion) at − 80 °C until process-
ing. Clinical data were recorded on admission: age, gen-
der, smoking history, Eastern Cooperative Oncology
Group (ECOG) performance status (PS), preoperative
pulmonary function tests (PFT) and chronic obstructive
pulmonary disease (COPD). COPD was defined as when
forced expiratory volume in 1 s (FEV1) to forced vital
capacity (FVC) ratio is below a fixed cutoff (< 70%).
Type of surgical resection and pathological findings were
also recorded, including tumor characteristics and the
presence of emphysema (defined histopathologically in
the resected non-tumoral tissue). All patient samples
were studied by Sanger sequencing for mutations in
TP53 (exons 5–8) and KRAS (codon 12–13), and only
adenocarcinoma patients samples were studied for EGFR
mutations (exons 19–21). The following primers were
used: TP53 exon 5 Forward (F) 5′- GTTTCTTTGCTG
CCGTCTTC-3′, TP53 exon 5 Reverse (R) 5′-GAGC
AATCAGTGAGGAATCAGA-3′; TP53 exon 6 F 5′-AG
AGACGACAGGGCTGGTT-3′, TP53 exon 6 R 5′-CT
TAACCCCTCCTCCCAGAG-3′; TP53 exon 7 F 5′-
TTGCCACAGGTCTCCCCAA-3′, TP53 exon 7 R 5′-A
GGGGTCAGAGGCAAGCAGA-3′; and TP53 exon 8 F
5′-GGGACAGGTAGGACCTGATTT-3′, TP53 exon 8
R 5′-TAACTGCACCCTTGGTCTCC-3′; KRAS F 5′-T
TAACCTTATGTGTGACATGTT-3′, KRAS R 5′-AGA
ATGGTCCTGCACCAGTAA-3′; EGFR exon 18 F 5′-
GCATGGTGAGGGCTGAGGT-3′, EGFR exon 18 R
5′-TGCAAGGACTCTGGGCTCC-3′,EGFR exon 19 F
5′-TGCATCGCTGGTAACATCCA-3′, EGFR exon 19 R
5′-GAAAAGGTGGGCCTGAGGTT-3′, EGFR exon 20
F 5′-TCCTTCTGGCCACCATGC-3′, EGFR exon 20 R
5′-TGGCTCCTTATCTCCCCTCC-3′, EGFR exon 21 F
5′-ATGCAGAGCTTCTTCCCATGA-3′, EGFR exon 21
R 5′-CAGGAAAATGCTGGCTGACC-3′.
All patients signed the written consent in accordance
with the Declaration of Helsinki to use their samples in
the present research. The Clinical Research Ethics Com-
mittee of the Hospital Clínic de Barcelona approved the
study.
NSCLC patients from The Cancer Genome Atlas
(TCGA) Research Network (RNAseq data; https://can-
cergenome.nih.gov) were used as a validation data set.
Two cohorts were used: the Lung Adenocarcinoma
(TCGA-LUAD) and the Lung Squamous Cell Carcinoma
(TCGA-LUSC). The patient selection criteria were: stage
I-II, Caucasian, minimum OS of 35 days, and available
RNAseq data. Using these selection criteria, the valid-
ation cohorts included 91 adenocarcinomas from the
TCGA-LUAD and 59 squamous cell carcinomas from
the TCGA-LUSC cohort. The analysis was performed
separately in each cohort.
RNA extraction and lncRNA expression analysis
Total RNA was purified from frozen tissue with TriZol®
Reagent (Life Technologies) as per manufacturer’s specifi-
cations. cDNA was synthetized from 500 ng of total RNA
with The High Capacity cDNA Reverse Transcription Kit®
(Applied Biosystems). TaqMan assays (Life Technologies)
were used to quantify HOTTIP (Hs00955374_s1) in a
7500 Real Time PCR device (Applied Biosystems).
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CDKN1B (Hs00153277_m1) was used as endogenous con-
trol, and the mean of the HOTTIP expression in the nor-
mal tissue was used as calibrator sample to apply
the2-ΔΔCt method.
Statistics
R v3.3 and IBM SPSS Statistics 22 were used for statistical
analysis. TTR was calculated as the time between surgery
and relapse or last follow-up and OS as the time between
surgery and death from any cause or last follow-up.
Kaplan-Meier survival curves and log-rank test were used
for the survival analysis. All clinic-pathological factors with
p-value ≤0.1 in the univariate analysis were included in the
Cox multivariate regression analyses. The Optimal cutoff for
the analysis of the impact on survival of the HOTTIP ex-
pression was identified using the Maxstat package (R Statis-
tical Package) and validated by the Kaplan-Meier test. Paired
(when necessary) or non-paired t-tests were used for com-
parisons between two groups. The independent validation of
the prognostic role of HOTTIP levels were performed using
TANRIC [28] (http://ibl.mdanderson.org/tanric/_design/




The main clinic-pathological characteristics of the pa-
tients are summarized in Table 1. Briefly, the mean pa-
tient age was 66 years (range, 32–84), 77 patients
(77.8%) were male, 20 (20.2%) had Eastern Cooperative
Oncology Group (ECOG) performance status (PS) 0 and
79 (79.8%) had PS 1. Seventy-three (60.2%) patients were
diagnosed in stage I disease. Adenocarcinoma hist-
ology was found in fifty-five (55.5%) patients and 87
(87.9%) were active or former smokers. Median
follow-up time was 44 months (range, 8–98). After a
follow-up of 98 months, 31 (31.3%) patients experi-
enced disease recurrence. Twenty-three patients
(23.2%) received adjuvant therapy after surgery (17
stage II and six stage IB). Thirty-three percent of the
patients harbored TP53 mutations and 20% harbored
KRAS mutations. Adenocarcinoma patients with EGFR
mutations (29.8%) showed a trend towards shorter
TTR (p = 0.09) and OS (p = 0.09).
HOTTIP expression and clinical characteristics
Patients with squamous cell carcinoma had significantly
higher levels of HOTTIP than those with adenocarcin-
oma (p = 0.007; Fig. 1a). HOTTIP was also overexpressed
in current and former smokers in comparison with
never-smokers (p = 0.02; Fig. 1b) and in former smokers
of < 15 years compared to former smokers of > 15 years
although this difference was not significant (data not
shown). Patients with PS 1 had higher levels of HOTTIP
than those with PS 0 (p = 0.08). No association was ob-
served between HOTTIP levels and TP53, KRAS or
EGFR mutational status.
Table 1 Main clinical characteristics of the patients
Characteristics Value N = 99
N (%)
Sex Male 77 (77.8)
Female 22 (22.2)
Age, yrs. Mean (Range) 66 (32–84)
<=65 49 (49.5)
> 65 50 (50.5)
ECOG PSa 0 20 (20.2)
1 79 (79.8)
Stage I 73 (73.7)
II 26 (26.3)
T 1 47 (47.5)
2 49 (49.5)
3 3 (3)
N 0 88 (88.9)
1 11 (11.1)
Histology Adenocarcinoma 55 (55.5)
Squamous cell carcinoma 36 (36.4)
Others 8 (8.1)
Type of surgery Lobectomy/bilobectomy 89 (89.9)
Pneumonectomy 4 (4)
Atypical Resectionb 6 (6.1)
Smoking history Current Smoker 34 (34.4)
Former Smoker 53 (53.5)
Never smoker 12 (12.1)
Adjuvant chemotherapy Yes 23 (23.2)
No 76 (76.8)
Relapse No 68 (68.7)
Yes 31 (31.3)
Emphysema Yes 48 (48.5)
No 44 (44.4)
Unknown 7 (7.1)
COPDc Yes 64 (64.6)
No 35 (35.4)
DLCOd (%) Mean (Range) 73.4 (35–101)
Molecular features TP53 mutations 31/94 (33)
KRAS mutations 20/98 (20.4)
EGFR mutationse 14/47 (29.8)
aECOG PS, Eastern Cooperative Oncology Group performance status
bAtypical resection refers to Wedge resection, a non-anatomic limited
resection of a lung portion
cCOPD, chronic obstructive pulmonary disease
dDLCO, diffusing capacity of the lung for carbon monoxide
eEGFR mutational status was assessed only in adenocarcinoma patients
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HOTTIP expression and clinical outcome
HOTTIP was expressed in all samples. Using the cutoff
identified by the Maxstat package of R, patients were in-
cluded depending on HOTTIP expression level into the
high (n = 43) or the low (n = 56) group. The cutoff iden-
tified coincided with the Mean + SD of HOTTIP expres-
sion in the normal tissue (Additional file 1: Figure S1).
Patients with high levels of HOTTIP had shorter TTR
(78.3 vs 58 months; p = 0.05) and shorter OS (81.2 vs 61
months; p = 0.02) than those with low levels (Fig. 2).
The univariate Cox analysis for all clinical variables
and for HOTTIP levels are shown in Table 2. In the
multivariate analysis for TTR, including sex and HOT-
TIP levels, only HOTTIP levels emerged as a significant
marker (Hazard ratio [HR]: 2.05; 95% confidence interval
[CI]: 1–4.22; p = 0.05). The multivariate analysis for OS,
including sex, age, PS, smoking status, emphysema, and
HOTTIP levels, identified age > 65 (HR: 2.72; 95%CI:
1.04–5.13; p = 0.01) and HOTTIP levels (HR: 2.31,
95%CI: 1.04–5.13; p = 0.04) as independent prognostic
markers (Table 3).
Independent validation of HOTTIP prognostic impact
using TCGA data
Using TCGA data and the TANRIC web tool, we found
that high levels of HOTTIP were associated with shorter
OS (p = 0.025) in a cohort of 91 stage I-II patients with
lung adenocarcinoma (Fig. 3a). However, the same ana-
lysis in the TCGA cohort of 59 stage I-II patients with
squamous cell carcinoma of the lung showed no signifi-
cant differences (p = 0.69, Fig. 3b).
A B
Fig. 1 HOTTIP expression according to (a) histology and (b) smoking status. ADK, adenocarcinoma; SCC, squamous cell carcinoma
A B
Fig. 2 a Time to relapse and (b) overall survival according to HOTTIP levels
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Analysis of HOTTIP correlation with TCGA mRNA and
miRNA data
Using TANRIC and TCGA lung adenocarcinoma patients,
we identified 1203 mRNAs and 61 miRNAs that signifi-
cantly correlated with HOTTIP expression (p < 0.05). The
most significant mRNA was HOXA13 (r = 0.7, p < 0.001).
Moreover, other HOXA genes were among the top 100
mRNAs, including HOXA9 (r = 0.51, p < 0.001), HOXA11
(r = 0.48, p < 0.001), and HOXA10 (r = 0.44, p < 0.001).
The Induced Network Module Analysis tool from Con-
sensus PathDB (http://cpdb.molgen.mpg.de/CPDB)
showed that most of the genes whose expression corre-
lated with HOTTIP were closely related to the HOX gene
network (Fig. 4a). One of the most significant miRNAs
identified was miR-196b (r = 0.44, p < 0.001), which is the
only miRNA located in the HOXA genomic region. We
then used miR-Path v.3 [29] to study the putative path-
ways regulated by this HOTTIP-miRNA signature and
identified 49 KEGG pathways (p < 0.05). The most signifi-
cant pathway identified was the Hippo signaling pathway
(p < 0.001), where 86 genes are Tarbase-validated targets
of 28 of the miRNAs included in the signature.
Other relevant KEGG pathways identified were the
TGF-beta signaling pathway, Cell cycle, Signaling
pathways regulating pluripotency of stem cells, Wnt sig-
naling pathway and p53 signaling pathway (Fig. 4b).
Additional file 2 includes the list of the top 100
mRNAs and all 61 miRNAs identified.
Discussion
HOTTIP is one of the lncRNAs located in the HOXA
genomic region of chromosome 7. The HOX genes are
crucial transcription factors that determine the identity
of cells and tissues during embryogenesis [30]. In adult
tissues, HOX genes play a role in normal hematopoiesis
regulation and are overexpressed in hematological [31]
and solid cancers [10], including NSCLC [14]. Specific-
ally, the HOXA gene cluster, where HOTTIP is found,
plays a critical role in the patterning of tissues with
mesodermal components, such as the lung, and in the
regulation of epithelial–mesenchymal interactions [32].
HOTTIP has been related to tumor metastasis through
induction of epithelial-mesenchymal transition [33].
In the present study, we have examined the role of
HOTTIP as a prognostic factor in early-stage NSCLC
patients treated with curative surgery and found that
Table 2 Cox univariate analyses of time to relapse and overall
survival
Hazard Ratio (95%CI) p-value
Time to Relapse
Male sex 3.039 (0.924–9.999) 0.067
Age > 65 1.207 (0.596–2.443) 0.602
PS 1 1.738 (0.607–4.972) 0.303
Stage II 0.888 (0.397–1.989) 0.773
T3 1.213 (0.159–9.275) 0.853
N1 1.142 (0.399–3.272) 0.805
Histology-Adenocarcinoma 0.860 (0.402–1.840) 0.698
Type of surgery-Pneumonectomy 4.812 (0.494–46.847) 0.176
Smoker 1.295 (0.632–2.656) 0.480
Adjuvant chemotherapy-Yes 0.890 (0.382–2.072) 0.787
Emphysema 1.121 (0.540–2.329) 0.759
COPD 1.131 (0.532–2.403) 0.749
TP53 mutated 1.841 (0.888–3.814) 0.101
KRAS mutated 1.217 (0.544–2.721) 0.633
EGFR mutated 2.334 (0.845–6.450) 0.102
High HOTTIP levels 2.047 (0.992–4.224) 0.053
Overall Survival
Male sex 3.748 (0.889–15.8) 0.072
Age > 65 2.628 (1.185–5.829) 0.017
PS 1 6.726 (0.914–49.520) 0.061
Stage II 0.720 (0.291–1.781) 0.478
T3 1.486 (0.192–11.507) 0.705
N1 0.585 (0.139–2.469) 0.466
Histology Adenocarcinoma 0.763 (0.336–1.732) 0.518
Type of surgery- Pneumonectomy 1.515 (0.213–10.797) 0.678
Smoker 0.387 (0.156–0.959) 0.040
Adjuvant chemotherapy- Yes 1.082 (0.459–2.549) 0.857
Emphysema 1.948 (0.897–4.230) 0.092
COPD 1.115 (0.504–2.467) 0.788
TP53 mutated 1.271 (0.568–2.844) 0.560
KRAS mutated 1.124 (0.477–2.646) 0.789
EGFR mutated 2.551 (0.822–7.916) 0.105
High HOTTIP levels 2.442 (1.1–5.418) 0.028
Table 3 Multivariate analyses of time to relapse and overall
survival
Hazard Ratio (95% CI) p-value
Time to Relapse
Male sex 2.71 (0.82–8.99) 0.10
High HOTTIP expression 2.05 (1–4.22) 0.05
Overall Survival
Male sex 3.25 (0.76–13.84) 0.11
Age > 65 2.72 (1.23–6.04) 0.01
ECOG PS 1a 4.04 (0.54–30.17) 0.17
Smoker 0.60 (0.06–5.3) 0.66
Emphysema 1.5 (0.68–3.34) 0.32
High HOTTIP expression 2.31 (1.04–5.13) 0.04
aECOG PS, Eastern Cooperative Oncology Group performance status
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patients with higher levels of HOTTIP had shorter TTR
and shorter OS than patients with low levels. More-
over, HOTTIP emerged as an independent prognostic
factor in the multivariate analysis. The prognostic role
of HOTTIP levels has been described in several can-
cers [19, 20, 22–25] and analyzed in several
meta-analyses [26, 27, 34–36], which concluded that
high HOTTIP expression in cancer patients is associ-
ated with poor clinical outcome. However, to the best
of our knowledge, ours is the first study to provide
evidence that HOTTIP impacts prognosis in NSCLC.
Additionally, we validated our findings on the prog-
nostic value of HOTTIP levels in another patient popula-
tion using TGCA data and the TANRIC webtool [28],
showing that HOTTIP impacts prognosis in NSCLC pa-
tients with adenocarcinoma but not in those with squa-
mous cell carcinoma. In our cohort, tumor HOTTIP
levels were significantly overexpressed in squamous cell
carcinoma compared to adenocarcinoma. While this
may suggest that the prognostic impact of HOTTIP
could differ between the main histological subtypes, the
sub-analysis in the different histological subtypes in our
cohort (Additional file 3: Figure S2) did not produce
conclusive results, probably due to the small size of the
sub-groups (55 adenocarcinomas and 36 squamous cell
carcinomas). However, in both cases, high HOTTIP
levels were associated with shorter TTR and shorter OS.
Previous studies have reported that disordered patterns
of HOX gene expression – specifically, HOXA1, HOXA5
and HOXA10 – are involved not only in the develop-
ment of NSCLC but also in histological diversity [13].
HOTTIP is located close to the 3′ region of HOXA10
and we observed a positive correlation in the expression
of the two genes in the in silico analysis of TCGA data.
We also observed a significant upregulation of HOT-
TIP in current and former smokers in comparison with
never smokers. An in vivo study showed that cigarette
smoke increases mRNA and protein levels of HOXA in
endometrial cells [37]. Interestingly, in our cohort,
former smokers of > 15 years showed lower levels of
HOTTIP than former smokers of < 15 years although
this difference was not significant.
Finally, since regulatory interactions between lncRNAs,
mRNAs and miRNAs have been described [38], we ex-
plored a possible association between the mRNAs and
miRNAs whose expression correlated with HOTTIP ac-
cording to TGCA data on adenocarcinoma NSCLC ana-
lyzed with TANRIC. This analysis identified a signature of
1203 mRNAs and 61 miRNAs. When we focused on the
top 100 mRNAs, we observed that most of the genes
whose mRNA expression correlated with HOTTIP expres-
sion were closely related to the HOX gene network, in-
cluding HOXA9, HOXA10, HOXA11, HOXA13, and other
HOX cluster members, such as HOXB13. Several studies
have reported that interactions between HOTTIP and
some of these HOX genes promote tumorigenesis. In
prostate cancer, HOTTIP forms a complex with the tran-
scription factor TWIST1 and with WDR5 and produces
upregulation of HOXA9 levels through chromatin regula-
tion which correlates with an aggressive cellular pheno-
type [39]. Moreover, HOTTIP modulates cancer stem cell
properties by binding WDR5 and activating HOXA9,
which enhances the Wnt/β-catenin pathway in prostate
cancer stem cells [40]. In pancreatic cancer cells, HOTTIP
regulates HOXA10, HOXB2, HOXA11, HOXA9 and
HOXA1, but not HOXA13 [41]. However, HOTTIP and
HOXA13 have been associated with disease progression
and worse outcome in hepatocellular carcinoma [22], with
progression and gemcitabine resistance in pancreatic can-
cer [42], and with tumorogenesis and metastasis in
esophageal squamous carcinoma [43] and gastric cancer
[44]. In line with our results in NSCLC patient samples,
these studies have shown that HOTTIP upregulation is as-
sociated with increased levels of HOXA13. In contrast,
A B
Fig. 3 Independent validation of HOTTIP as prognostic marker in (a) TCGA lung adenocarcinoma (LUAD) patients and (b) TCGA squamous cell
carcinoma (LUSC) patients
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however, an in vitro study in the A549 NSCLC cell line
showed that silencing HOTTIP led to increased HOXA13
levels [21]. Although this study included only one cell line
and did not analyze the correlation between HOXA13 and
HOTTIP in patient samples, it showed that HOTTIP acts
as an oncogene, regulating apoptosis, proliferation, and
migration in NSCLC. Another study, by Zhang et al., also
reported the role of HOTTIP as oncogene in A549
through regulation of the AKT signaling pathway. The au-
thors showed that the overexpression of HOTTIP en-
hanced proliferation and paclitaxel resistance [45].
Further studies are needed to clarify this interaction,
including analyses in other NSCLC cell lines.
Interestingly, the network analysis also identified an add-
itional node that included HOXP, a transcription factor
related to alveolar differentiation, whose suppression has
been linked to increased invasiveness in adenocarcinoma
lung cancer [46]. There was a negative correlation be-
tween HOXP and HOTTIP levels, which could explain
the more aggressive phenotype we have observed in pa-
tients with high HOTTIP levels.
When we explored the miRNAs in the 61-miRNA sig-
nature identified in the TANRIC analysis, we found a
positive correlation with miR-196b, located in the distal
part of the same HOXA cluster, and with miR-196a-1, lo-
cated in the HOXB cluster. The study of the potential
A
B
Fig. 4 a Network analysis using the top 100 genes whose expression correlates with HOTTIP levels. The Induced Network Module Analysis tool
from Consensus PathDB was used. b DIANA-miRPath analysis using the miRNAs whose expression correlates with HOTTIP levels. DIANA-mirPath is
a miRNA pathway analysis web-server that examines a list of miRNAs provided by the user, identifies their potential/validated targets, and
performs a pathway analysis to identify the most relevant pathways regulated by the miRNAs. In the present study, experimentally validated
miRNA interactions derived from DIANA-Tarbase and KEGG analysis were used in the analysis. The KEGG signaling pathways identified are
ordered from left to right in descending order of p-value. The y-axis indicates the number of genes (dark blue) and miRNAs (light blue) identified
in the miRNA/target interaction analysis which are included in each KEGG pathway identified. For example, the Hippo signaling pathway is the
most significant pathway identified and included 28 miRNAs from the HOTTIP-related miRNA signature, which targets 86 genes included in the
Hippo signaling pathway
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pathways regulated by the miRNA signature showed the
importance of the Hippo signaling pathway, which has
previously been shown to be altered in NSCLC [47].
Conclusions
Our findings provide the first indication that HOTTIP may
be a prognostic biomarker in NSCLC. In line with the prog-
nostic impact of HOTTIP levels in other cancers, high
levels of HOTTIP correlated with worse TTR and worse
OS in our early-stage NSCLC patients. HOTTIP may be
useful for the identification of resected NSCLC patients at
high risk of relapse. Further investigation in a prospective
study is warranted to validate these findings and to examine
potential HOTTIP-based therapeutic approaches.
Additional files
Additional file 1: Figure S1. (A) Time to relapse and (B) overall survival
according to HOTTIP levels in adenocarcinoma patients. (C) Time to
relapse and (D) overall survival according to HOTTIP levels in squamous
cell carcinoma patients. (PPTX 57 kb)
Additional file 2: Excel file with the results of the analysis of HOTTIP
correlation with TCGA data that includes 2 sheets: mRNAs sheet, which
includes the list of the top 100 mRNAs; and miRNAs sheet with all 61
miRNAs identified. (XLSX 19 kb)
Additional file 3: Figure S2. Bar plot showing the 99 patients ordered
by HOTTIP expression level. An arrow shows the mean HOTTIP expression
in the normal tissue and the cutoff used to classify the patients in high
or low expression. The cutoff coincides with the Mean + SD of HOTTIP
expression in the normal tissue. (PPTX 104 kb)
Abbrebiations
ECOG: Eastern Cooperative Oncology Group; lncRNAs: long non-coding
RNAs; miRNAs: microRNAs; ncRNAs: non-coding RNAs; NSCLC: Non-small-cell
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